He started sharing secret details of the bapi study with Martoma on a regular basis. He told him about how the brain swelling could be a sign that the drug was working, how different doses appeared to be affecting the patients, how carriers of a specific gene tied to Alzheimer’s were responding. Martoma took it all in and pressed for more. He was especially interested in the number of patients showing side effects, the more specific the better. Gilman tried not to think about what Martoma was doing with the information he gave him.
